Compare Davita Inc (DVA) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Newmont Corporation — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Newmont Corporation trades at $117.76 (market cap $119.64B). The key difference: Newmont Corporation is far larger — about 10.6× Davita Inc's market cap, and Newmont Corporation pays a 0.92% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Newmont Corporation for 58 Days on average.
| DVA | NEM | |
|---|---|---|
Market Cap | $11.28B | $119.64B |
Volume | 650,294 | 4,343,460 |
Sector | Health | Basic Materials |
52-Week High | $240.96 | $135.14 |
52-Week Low | $103.87 | $78.63 |
Typical Hold Time | 113 Days | 58 Days |
Enterprise Value | $24.00B | $116.23B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
NEM trades at $115.55, down 0.72% on the day, with a bearish technical signal but strong fundamentals. Recent earnings beats and record free cash flow of $5.3B in H1 2026 highlight operational strength. The stock is supported by a 75.68% analyst buy rating and a consensus price target of $136.83, though it faces near-term resistance at $116.
The outlook remains positive given robust profitability and growth, but risks include gold price volatility and execution of per-share growth targets. Upside potential exists if the company continues to exceed earnings expectations and maintains its cash flow momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
